DOCSLIB.ORG

Dermatology Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dermatology Update 12/6/19 Dermatology Update Lindy P. Fox, MD Professor of Clinical Dermatology Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco [email protected] I have no conflicts of interest to disclose I may be discussing off-label use of medications 1 1 Outline • Principles of topical therapy • Chronic Urticaria • Alopecia • Acne in the adult • Perioral dermatitis • Sunscreens 2 2 1 12/6/19 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Moisturizers – Contain oil to seal the surface of the skin and replace the damaged water barrier – Petrolatum (Vaseline) is the premier and “gold standard” moisturizer – Additions: water, glycerin, mineral oil, lanolin – Some try to mimic naturally occurring ceramides (E.g. CeraVe) • Thick creams more moisturizing than pump lotions 3 Principles of Dermatologic Therapy Moisturizers and Gentle Skin Care • Emolliate skin – All dry skin itches • Gentle skin care – Soap to armpits, groin, scalp only – Short cool showers or tub soak for 15-20 minutes – Apply medications and moisturizer within 3 minutes of bathing or swimming 4 2 12/6/19 Principles of Dermatologic Therapy Topical Medications • The efficacy of any topical medication is related to: 1. The concentration of the medication 2. The vehicle 3. The active ingredient (inherent strength) 4. Anatomic location 5 Vehicles • Ointment (like Vaseline): – Greasy, moisturizing, messy, most effective. • Creams (vanish when rubbed in): – Less greasy, can sting, more likely to cause allergy (preservatives/fragrances). • Lotions (liquid): – Cooling, liquids that pour. 6 3 12/6/19 Vehicles • Solutions (liquids that are greasy or alcoholic): – Can sting, good for hairy areas • Gels (semi solid alcohol-based): – Can sting, good for hairy areas or wet lesions • Foams (cosmetically elegant): – For hairy areas • Sprays: Aerosols (rarely used) 7 Topical Corticosteroids • Super-High Potency: Clobetasol • High Potency: Fluocinonide • Medium Potency: Triamcinolone (TAC) • Mid-Low: Aclometasone, Desonide • Lowest Potency: Hydrocortisone 8 4 12/6/19 Topical Therapy • Choose agent by body site, age, type of lesion (weeping or not), surface area • For Face: – Hydrocortisone 2.5% ointment BID – If fails, aclometasone (Aclovate), desonide ointment • For Body: – Triamcinolone acetonide 0.1% ointment BID – If fails, fluocinonide ointment • For scalp: – Fluocinonide solution – Fluocinolone oil – Clobetasol foam 9 9 Chronic Urticaria 10 10 5 12/6/19 Question 1 Most patients with chronic urticaria 1. Have an identifiable underlying cause 2. Are undertreated 3. Relapse 4. Have associated constitutional symptoms 5. Require allergy testing 11 Question 1 Most patients with chronic urticaria 1. Have an identifiable underlying cause 2. Are undertreated 3. Relapse 4. Have associated constitutional symptoms 5. Require allergy testing 12 6 12/6/19 • 36 yoF complains of 2 mo of urticaria • Lesions last < 24 hours, itchy • Failed loratadine 10 mg daily 13 Chronic Urticaria • Urticaria, with or without angioedema > 6 weeks – Lesions last < 24 hours, itch, completely resolve • Divided into chronic spontaneous (66-93%) or chronic inducible • Natural history- 2-5 years – > 5 yrs in 20% patients – 13% relapse rate • Etiology – 30 -50 % - IgG autoAb to IgE or FcεRIα – Remainder, unclear Clin Transl Allergy 2017. 7(1): 1-10 Eur J Dermatol 2016 J Allergey Clin Immunol Pract. 2017. Sept 6. S2213-2198 14 7 12/6/19 Chronic Urticaria- Workup • History and physical guides workup • Labs to check – CBC with differential – ESR, CRP – TSH and thyroid autoantibodies – Liver function tests – CU Index (Fc-εRIα Ab or Ab to IgE) – Maybe tryptase for severe, chronic recalcitrant disease – Maybe look for bullous pemphigoid in an older patient • Provocation for inducible urticaria Eur J Dermatol 2016 Allergy Asthma Immunol Res. 2016;8(5):396-403 Clin Transl Allergy 2017. 7(1): 1-10 15 First line Chronic Spontaneous Urticaria- Treatment H1 antihistamines- 2nd generation <40% respond to standard dose H1 blockade Avoid triggers (NSAIDS, ASA) Can increase to up to 4X standard dose 60% chance of response Second line High dose 2nd generation AH Add another 2nd generation AH 1st gen H1 antihistamine QHS Third line +/- H2 antagonist Omalizumab +/- Leukotriene antagonist Cyclosporine Dapsone Sulfasalazine J Allergy Clin Immunol 2014. 133(3):914-5 BJD 2016. 175:1134–52 Hydroxychloroquine Clin Transl Allergy 2017. 7(1): 1-10 Mycophenolate mofetil Allergy Asthma Immunol Res. 2016;8(5):396-403 TNFα antagonists Eur J Dermatol 2016 (epub ahead of print) Allergy Asthma Immunol Res. 2017 November;9(6):477-482. Anti CD20 Ab (rituximab) Allergy 2018. Jan 15. epub ahead of print 16 8 12/6/19 What does my “second line” look like? • Fexofenadine 360 mg am, 180 mg noon, 360 mg pm • Cetirizine 10 mg BID • Hydroxyzine 25 mg QHS • +/- Monteleukast 10 mg QD • +/- Ranitidine 300 mg QD • Give epipens (3) • When time to taper, take off 1 pill per week 17 CSU- when to refer • Atypical lesion morphology or symptoms – > 24 hours, central duskiness/purpura – Asymptomatic or burn >> itch • Minimal response to medications – High dose H1 nonsedating antihistamines – H1 sedating antihistamines • Associated symptoms – Fever, fatigue, mylagias, arthralgias • Elevated ESR/CRP 18 9 12/6/19 More than Just Urticaria Rheumatic Fever Serum sickness-like reaction Adult Onset Stills Disease Rat bite fever Cryopyrin Associated Periodic Leptospirosis Syndrome Brucellosis Schnitzler syndrome Neutrophilic urticaria with systemic inflammation 19 Alopecia 20 20 10 12/6/19 Alopecia = hair loss Non-Scarring Scarring Alopecia areata Traction alopecia Trichotillomania (end stage) Telogen Effluvium Neutrophil mediated Androgenetic alopecia Folliculitis decalvans Dissecting cellulitis of the scalp Lymphocyte mediated Lichen planopilaris Frontal fibrosing alopecia Central centrifugal alopecia Chronic cutaneous lupus Scalp biopsy: 21 • Area ADJACENT to alopecia, ask for TRANSVERSE sections • ALL scarring alopecias OR nonscarring alopecia where diagnosis uncertain 21 Alopecia Areata • Affects up to 0.2% US population • Types – Relapsing remitting – Ophiasis (band like along occipital scalp) – Alopecia totalis (all scalp hair) – Alopecia universalis (all scalp and body hair) • Associations – Atopic disease – Autoimmune thyroid disease – Vitiligo – Inflammatory bowel disease – APECED syndrome 22 22 11 12/6/19 Alopecia Areata: Round or oval patches of nonscarring alopecia 23 Taken from Dermatology, 2012, Elsevier 23 Alopecia Areata: Exclamation point hairs 24 Taken from Dermatology, 2012, Elsevier 24 12 12/6/19 Alopecia Areata: Ophiasis pattern 25 Taken from Dermatology, 2012, Elsevier 25 Alopecia Areata • IL triamcinolone – 10mg/ml – q month • Immunosuppression (recurs after stopped) – Pulse steroids – Methotrexate – Cyclosporine • Contact sensitization • Minoxidil • Antihistamines • Simvastatin/ezetimibe • Tofacitinib J Investig Dermatol Symp Proc. 2018 Jan;19(1):S25-S31 J Investig Dermatol Symp Proc. 2018 Jan;19(1):S18-20 26 JAAD 2018 Jan; 78(1):15-24 26 13 12/6/19 Anagen 90-95% Catagen Normal Hair Cycle Telogen 5-10% Normal shedding is 50-100 hairs/d 27 Telogen Effluvium • Transient shifting of hair cycle • Shedding • No scalp itch or rash 28 28 14 12/6/19 Telogen Effluvium- Causes • Postpartum • Chronic (no cause) • Post febrile • Severe infection • Severe chronic illness (SLE, HIV, etc) • Severe prolonged stress • Post major surgery • Endocrinopathy – Thyroid, parathyroid • Crash diets, malnutrition, starvation • Medications – Stopping OCP, retinoids, heparin, PTU, methimazole, anticonvulsants, β- blockers, IFN-α, heavy metals 29 29 Telogen Effluvium • Examination – Diffuse thinning – Hair pull • Diagnostic • > 20% hairs are telogen – Look for bulb at end of hair shaft Front. Med. 4:112. 2017 30 30 15 12/6/19 Telogen Effluvium • Workup – TSH, Vit D, Fe, ferritin, chemistry – Biopsy if > 6 mo (r/o AGA) • Treatment – Address underlying etiology – Replete ferritin if < 40 ng/dl – Minoxidil 5% (foam) – Reassurance (most regrow almost all lost hair) 31 31 Androgenetic Alopecia • Male or female pattern hair loss • Female – Complain of widening part – Retain anterior hairline – Early onset/severe: workup for hyperandrogenism • F/T testosterone, DHEAS, 17-OH progesterone • Often “exposed” by telogen effluvium • Treat with – Minoxidil 5% (F QD, M BID) – Spironolactone (female) – Finasteride- up to 5mg/d • NOT for women of childbearing potential 32 32 16 12/6/19 33 Taken from Dermatology, 2012, Elsevier 33 Some scarring alopecias 34 34 17 12/6/19 Traction Alopecia 35 Taken from Dermatology, 2012, Elsevier 35 Chronic Cutaneous LE 36 Taken from Dermatology, 2012, Elsevier 36 18 12/6/19 Lichen Planopilaris 37 Taken from Dermatology, 2012, Elsevier 37 Approach to the Adult Acne Patient 38 38 19 12/6/19 Question 2 Which of the following regarding acne in women is TRUE 1. Spironolactone requires K+ monitoring 2. Abnormal follicular keratinization is the first step in the formation of acne 3. Tazarotene is safe in pregnancy 4. Most patients do not require a topical retinoid 39 Question 2 Which of the following regarding acne in women is TRUE 1. Spironolactone requires K+ monitoring 2. Abnormal follicular keratinization is the first step in the formation of acne 3. Tazarotene is safe in pregnancy 4. Most patients do not require a topical retinoid 40 20 12/6/19 Acne Pathogenesis, Clinical Features, Therapeutics Pathogenesis Clinical features Therapeutics Retinoids, Excess sebum Oily skin spironolactone Non-inflammatory
Load more

Recommended publications
  • Pediatric and Adolescent Dermatology
    Pediatric and adolescent dermatology Management and referral guidelines ICD-10 guide • Acne: L70.0 acne vulgaris; L70.1 acne conglobata; • Molluscum contagiosum: B08.1 L70.4 infantile acne; L70.5 acne excoriae; L70.8 • Nevi (moles): Start with D22 and rest depends other acne; or L70.9 acne unspecified on site • Alopecia areata: L63 alopecia; L63.0 alopecia • Onychomycosis (nail fungus): B35.1 (capitis) totalis; L63.1 alopecia universalis; L63.8 other alopecia areata; or L63.9 alopecia areata • Psoriasis: L40.0 plaque; L40.1 generalized unspecified pustular psoriasis; L40.3 palmoplantar pustulosis; L40.4 guttate; L40.54 psoriatic juvenile • Atopic dermatitis (eczema): L20.82 flexural; arthropathy; L40.8 other psoriasis; or L40.9 L20.83 infantile; L20.89 other atopic dermatitis; or psoriasis unspecified L20.9 atopic dermatitis unspecified • Scabies: B86 • Hemangioma of infancy: D18 hemangioma and lymphangioma any site; D18.0 hemangioma; • Seborrheic dermatitis: L21.0 capitis; L21.1 infantile; D18.00 hemangioma unspecified site; D18.01 L21.8 other seborrheic dermatitis; or L21.9 hemangioma of skin and subcutaneous tissue; seborrheic dermatitis unspecified D18.02 hemangioma of intracranial structures; • Tinea capitis: B35.0 D18.03 hemangioma of intraabdominal structures; or D18.09 hemangioma of other sites • Tinea versicolor: B36.0 • Hyperhidrosis: R61 generalized hyperhidrosis; • Vitiligo: L80 L74.5 focal hyperhidrosis; L74.51 primary focal • Warts: B07.0 verruca plantaris; B07.8 verruca hyperhidrosis, rest depends on site; L74.52 vulgaris (common warts); B07.9 viral wart secondary focal hyperhidrosis unspecified; or A63.0 anogenital warts • Keratosis pilaris: L85.8 other specified epidermal thickening 1 Acne Treatment basics • Tretinoin 0.025% or 0.05% cream • Education: Medications often take weeks to work AND and the patient’s skin may get “worse” (dry and red) • Clindamycin-benzoyl peroxide 1%-5% gel in the before it gets better.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Fucidin H Cream Patient Leaflet
    Scale Get-up Material No Sent by e-maiL l 100% GB 059516-XX Subject Date Date INS 175 x 280 mm 02/04/19 Colour Sign. Sign. Black RBE Preparation Place of production 213 Strength ® Packsize Fucidin H cream Ireland Comments: Page 1 of 2 Pharmacode 213 Font size: Heading: 9 pt, section: 8 pt, linespacing: 3 mm Mock-up for reg. purpose 175 mm IIE007-01 - 175 x 280 mm 175 x 280m Insert 100% PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin® H cream Fusidic acid and hydrocortisone acetate m Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. 20/01/2004 11/06/2018 IIE007-01 What is in this leaflet: Other medicines and Fucidin H cream 213 1. What Fucidin® H cream is and what it is used for Tell your doctor or pharmacist if you are taking, or have 2. Before you use Fucidin® H cream recently taken or might take any other medicines. 3. How to use Fucidin® H cream 4. Possible side effects Pregnancy and breast-feeding 5.
    [Show full text]
  • Acute-Onset Alopecia
    PHOTO CHALLENGE Acute-Onset Alopecia Justin P. Bandino, MD; Dirk M. Elston, MD A previously healthy 45-year-old man presented to the dermatology department with abrupt onset of patchy, progressively worsening alopecia of the scalp as well as nausea with emesis and blurry vision of a few weeks’ duration. All symptoms were temporally associated with a new demoli- tion job the patient had started at an industrial site. He reportedcopy 10 other contractors were simi- larly affected. The patient denied paresthesia or other skin changes. On physical examination, large patches of smooth alopecia without ery- thema,not scale, scarring, tenderness, or edema that coalesced to involve the majority of the scalp, eye- brows, and eyelashes (inset) were noted. Do WHAT’S THE DIAGNOSIS? a. alopecia areata b. dioxin-induced alopecia c. phosgene-induced alopecia d. syphilitic alopecia CUTIS e. thallium-induced alopecia PLEASE TURN TO PAGE E25 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]). E24 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2019. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Thallium-Induced Alopecia t the time of presentation, a punch biopsy speci- pencil point–shaped fractures that shed approximately men of the scalp revealed nonscarring alopecia 1 to 2 months after injury. The 10% of scalp hairs in A with increased catagen hairs; follicular minia- the resting telogen phase have no matrix and thus are turization; peribulbar lymphoid infiltrates; and fibrous unaffected.
    [Show full text]
  • Also Called Androgenetic Alopecia) Is a Common Type of Hereditary Hair Thinning
    750 West Broadway Suite 905 - Vancouver BC V5Z 1H8 Phone: 604.283.9299 Fax: 604.648.9003 Email: [email protected] Web: www.donovanmedical.com Female Pattern Hair Loss Female pattern hair loss (also called androgenetic alopecia) is a common type of hereditary hair thinning. Although hair may become quite thin, women do not become bald as in men. Hair thinning starts as early as the teenage years, but usually in the twenties and thirties and is usually fully expressed by the age of 40. How can one recognize female pattern hair loss? § Typically, a female in her teens, twenties or thirties gradually becomes aware that she has less hair on the top of her head than previously. § She may notice that her scalp has become slightly visible now and it takes more effort to style the hair to hide the thinning. § The size of the ponytail becomes smaller in diameter. § While all this is happening, she may also notice that her hair becomes greasy and stringy more quickly and she shampoos more often to keep the hair looking fuller volume. § One of the earliest signs of androgenetic alopecia is widening of the ‘central part’ (down the middle of the scalp). The spacing between hairs gradually increases. The thinning gradually becomes diffuse and may be present all over the scalp but is usually most pronounced over the top and sides of the head. § There is much variation in the diameter and length of hairs – some and thick and long while others are fine and short. This variation in size represents the gradual miniaturization of hair follicles- they become smaller and smaller.
    [Show full text]
  • Short Anagen Syndrome: a Case Study
    Journal of Cosmetics, Dermatological Sciences and Applications, 2012, 2, 14-15 http://dx.doi.org/10.4236/jcdsa.2012.21004 Published Online March 2012 (http://www.SciRP.org/journal/jcdsa) Short Anagen Syndrome: A Case Study Martina Alés Fernández, Francisco M. Camacho Martínez Department of Dermatology, Virgen Macarena University Hospital, Seville, Spain. Email: [email protected], [email protected] Received October 31st, 2011; revised November 18th, 2011; revised November 29th, 2011 ABSTRACT Short anagen syndrome is a relatively recently described entity. This syndrome is an unusual condition where the ana- gen growth phase of hair follicles is shorter than normal. Its clinical characteristics and trichogram findings contribute to the diagnosis of this trichosis. Keywords: Anagen Syndrome 1. Case Report Three-years-old girl with low density and slow growth scalp hair that had not been cut since birth. Her birth and medical history were unremarkable. The physical ex- amination revealed short and fine brown scalp hair with decreased density in frontoparietal areas (Figure 1). The rest of the physical examination was normal, without any abnormalities in eyelashes, eyebrows, teeth, nails or skin. The hair pull test was negative. The trichogram demon- strated some dystrophic hairs, but the most important data was an increased number of telogen hairs with a consistent decreased number of anagen hairs (Figure 2). The anagen to telogen ratio (7:28) was significantly re- duced with only 25% of hairs in anagen. 2. Discussion Short anagen syndrome is a relatively recently recog- nized entity poorly documented. Short hair due to a short anagen phase was described in 1987 by Kersey as part of tricho-dental syndrome [1].
    [Show full text]
  • Hypertrichosis in Alopecia Universalis and Complex Regional Pain Syndrome
    NEUROIMAGES Hypertrichosis in alopecia universalis and complex regional pain syndrome Figure 1 Alopecia universalis in a 46-year- Figure 2 Hypertrichosis of the fifth digit of the old woman with complex regional complex regional pain syndrome– pain syndrome I affected hand This 46-year-old woman developed complex regional pain syndrome (CRPS) I in the right hand after distor- tion of the wrist. Ten years before, the diagnosis of alopecia areata was made with subsequent complete loss of scalp and body hair (alopecia universalis; figure 1). Apart from sensory, motor, and autonomic changes, most strikingly, hypertrichosis of the fifth digit was detectable on the right hand (figure 2). Hypertrichosis is common in CRPS.1 The underlying mechanisms are poorly understood and may involve increased neurogenic inflammation.2 This case nicely illustrates the powerful hair growth stimulus in CRPS. Florian T. Nickel, MD, Christian Maiho¨fner, MD, PhD, Erlangen, Germany Disclosure: The authors report no disclosures. Address correspondence and reprint requests to Dr. Florian T. Nickel, Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany; [email protected] 1. Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in complex regional pain syndromes: analysis of 145 cases. Acta Neurol Scand 2000;101:262–269. 2. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001;57:2179–2184. Copyright © 2010 by
    [Show full text]
  • Hair That Does Not Grow: Loose Anagen Hair Syndrome Versus Short Anagen Hair Syndrome
    Central Annals of Pediatrics & Child Health Clinical Image *Corresponding author Norma E.Vázquez-Herrera, Hospital Zambrano Hellion Batallón San Patricio 112 Col. Real de San Agustín, San Hair That Does Not Grow: Pedro Garza García, México, Tel: 5281888880650; Email: Submitted: 03 March 2016 Loose Anagen Hair Syndrome Accepted: 29 April 2016 Published: 03 May 2016 Versus Short Anagen Hair Copyright © 2016 Vázquez-Herrera et al. Syndrome OPEN ACCESS Keywords Vázquez-Herrera NE1*, Sharma D2, Tosti A3 • Loose anagen hair syndrome • LAHS 1Departamen of MedicinaInterna, Tecnológico de Monterrey, México • Short anagen hair syndrome 2 Rutgers University, New Jersey Medical School, USA • SAHS 3 Department of Dermatology and Cutaneous Surgery, University of Miami, USA • Trichogram • Alopecia Abstract • Hair disorder • Pediatric hair loss Loose anagen hair syndrome (LAHS) is a hair disorder that is caused by defective • Painless extraction of hair anchorage of the hair shaft to the follicle and primarily affects children. Diagnosis is • Hair that will not grow made clinically by painless plucking of hair that does not grow long and confirmed • Short hair in child by a trichogram with distrophic anagen hairs. Short anagen hair syndrome (SAHS) is another hair condition in which anagen phase has a short duration and as a result, patients present with very short hair and often complain of increased shedding. In this second pathology, pull test shows extraction of telogen hairs with a pointed tip. Both of these diseases must be considered in pediatric patients that present with a complaint of hair that does not grow long. CLINICAL IMAGE encoding for companion layer keratin (K6HF) in patients with LAHS and wooly hair syndrome.
    [Show full text]
  • Alopecia Areata: Evidence-Based Treatments
    Alopecia Areata: Evidence-Based Treatments Seema Garg and Andrew G. Messenger Alopecia areata is a common condition causing nonscarring hair loss. It may be patchy, involve the entire scalp (alopecia totalis) or whole body (alopecia universalis). Patients may recover spontaneously but the disorder can follow a course of recurrent relapses or result in persistent hair loss. Alopecia areata can cause great psychological distress, and the most important aspect of management is counseling the patient about the unpredictable nature and course of the condition as well as the available effective treatments, with details of their side effects. Although many treatments have been shown to stimulate hair growth in alopecia areata, there are limited data on their long-term efficacy and impact on quality of life. We review the evidence for the following commonly used treatments: corticosteroids (topical, intralesional, and systemic), topical sensitizers (diphenylcyclopropenone), psor- alen and ultraviolet A phototherapy (PUVA), minoxidil and dithranol. Semin Cutan Med Surg 28:15-18 © 2009 Elsevier Inc. All rights reserved. lopecia areata (AA) is a chronic inflammatory condition caus- with AA having nail involvement. Recovery can occur spontaneously, Aing nonscarring hair loss. The lifetime risk of developing the although hair loss can recur and progress to alopecia totalis (total loss of condition has been estimated at 1.7% and it accounts for 1% to 2% scalp hair) or universalis (both body and scalp hair). Diagnosis is usu- of new patients seen in dermatology clinics in the United Kingdom ally made clinically, and investigations usually are unnecessary. Poor and United States.1 The onset may occur at any age; however, the prognosis is linked to the presence of other immune diseases, family majority (60%) commence before 20 years of age.2 There is equal history of AA, young age at onset, nail dystrophy, extensive hair loss, distribution of incidence across races and sexes.
    [Show full text]
  • Hair and Nail Disorders
    Hair and Nail Disorders E.J. Mayeaux, Jr., M.D., FAAFP Professor of Family Medicine Professor of Obstetrics/Gynecology Louisiana State University Health Sciences Center Shreveport, LA Hair Classification • Terminal (large) hairs – Found on the head and beard – Larger diameters and roots that extend into sub q fat LSUCourtesy Health of SciencesDr. E.J. Mayeaux, Center Jr., – M.D.USA Hair Classification • Vellus hairs are smaller in length and diameter and have less pigment • Intermediate hairs have mixed characteristics CourtesyLSU Health of E.J. Sciences Mayeaux, Jr.,Center M.D. – USA Life cycle of a hair • Hair grows at 0.35 mm/day • Cycle is typically as follows: – Anagen phase (active growth) - 3 years – Catagen (transitional) - 2-3 weeks – Telogen (preshedding or rest) about 3 Mon. • > 85% of hairs of the scalp are in Anagen – Lose 75 – 100 hairs a day • Each hair follicle’s cycle is usually asynchronous with others around it LSU Health Sciences Center – USA Alopecia Definition • Defined as partial or complete loss of hair from where it would normally grow • Can be total, diffuse, patchy, or localized Courtesy of E.J. Mayeaux, Jr., M.D. CourtesyLSU of Healththe Color Sciences Atlas of Family Center Medicine – USA Classification of Alopecia Scarring Nonscarring Neoplastic Medications Nevoid Congenital Injury such as burns Infectious Systemic illnesses Genetic (male pattern) (LE) Toxic (arsenic) Congenital Nutritional Traumatic Endocrine Immunologic PhysiologicLSU Health Sciences Center – USA General Evaluation of Hair Loss • Hx is
    [Show full text]
  • Case of Persistent Regrowth of Blond Hair in a Previously Brunette Alopecia Areata Totalis Patient
    Case of Persistent Regrowth of Blond Hair in a Previously Brunette Alopecia Areata Totalis Patient Karla Snider, DO,* John Young, MD** *PGYIII, Silver Falls Dermatology/Western University, Salem, OR **Program Director, Dermatology Residency Program, Silver Falls Dermatology, Salem, OR Abstract We present a case of a brunette, 64-year-old female with no previous history of alopecia areata who presented to our clinic with diffuse hair loss over the scalp. She was treated with triamcinolone acetonide intralesional injections and experienced hair re-growth of initially white hair that then partially re-pigmented to blond at the vertex. Two years following initiation of therapy, she continued to have blond hair growth on her scalp with no dark hair re-growth and no recurrence of alopecia areata. Introduction (CBC), comprehensive metabolic panel (CMP), along the periphery of the occipital, parietal and Alopecia areata (AA) is a fairly common thyroid stimulating hormone (TSH) test and temporal scalp), sisaipho pattern (loss of hair in autoimmune disorder of non-scarring hair loss. antinuclear antibody (ANA) test. All values were the frontal parietotemporal scalp), patchy hair unremarkable, and the ANA was negative. The loss (reticular variant) and a diffuse thinning The disease commonly presents as hair loss from 2 any hair-bearing area of the body. Following patient declined a biopsy. variant. Often, “exclamation point hairs” can be hair loss, it is not rare to see initial growth of A clinical diagnosis of alopecia areata was seen in and around the margins of the hair loss. depigmented or hypopigmented hair in areas made. The patient was treated with 5.0 mg/mL The distal ends of these hairs are thicker than the proximal ends, and they are a marker of active of regrowth in the first anagen cycle.
    [Show full text]
  • Teletrichology: a New Tool During the Covid-19 Emergency Teletricología: Una Nueva Herramienta Durante La Emergencia Sanitaria Por El Covid-19
    DermatologíaCMQ2021;19(2):194-195 PERLA DERMATOPATOLÓGICA Teletrichology: A New Tool During the COVID-19 Emergency Teletricología: una nueva herramienta durante la emergencia sanitaria por el COVID-19 Sonia Sofía Ocampo-Garza,1,2 Jorge Ocampo-Candiani,1 Gabriella Fabbrocini,2 Massimiliano Scalvenzi2 y Alessia Villani2 1 Departamento de Dermatología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León 2 Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy ABSTRACT RESUMEN Telemedicine will probably play a more permanent role during Durante la pandemia por el COVID-19 la telemedicina ha ocupado and after the COVID-19 pandemic. Teletrichology was described un rol muy importante, el cual seguramente continuará como for hair disorders including androgenetic alopecia, alopecia parte de la dermatología a nivel mundial. La teletricología se ha areata, telogen effluvium, and some scarring alopecias. We descrito para diagnosticar y tratar diferentes enfermedades del would like to share our own experience in order to encourage cuero cabelludo, entre ellas la alopecia androgenética, la alopecia the use of teletrichology among dermatologists. areata, el efluvio telógeno, así como algunas alopecias cicatricia- les. En este artículo queremos compartir con otros dermatólogos KEYWORDS: teledermatology, telemedicine, teletrichology, COVID-19, nuestra experiencia para incentivar el uso de la teletricología. trichoscopy, alopecia, hair loss. PALABRAS CLAVE: teledermatología, telemedicina, teletricología, COVID-19, tricoscopia, alopecia, pérdida de cabello. Dear editor: scarring alopecias.1 We would like to share our own ex- n late 2019 the novel coronavirus spread throughout perience in order to encourage the use of teletrichology Ithe world; causing many dermatology departments among dermatologists.
    [Show full text]